reduced activity motivation appears when people begin GLP‑1 medications. A study presented at ENDO 2026 tracked 753 adults using Fitbit data. After starting a GLP‑1, their daily steps fell about 11% (from roughly 5,047 to 4,487 per day), and moderate‑to‑vigorous activity dropped by around 21% (from 28 to 22 minutes daily) (reddit.com). Healthline reported the same pattern: Fitbit users showed lower step counts and less moderate‑to‑vigorous activity after beginning GLP‑1s like Ozempic and Wegovy (healthline.com).
People drop movement even as weight falls, when physics should make movement easier. Mouse research offers a clue. Semaglutide in mice cut voluntary wheel running and lowered effort to access the wheel, independent of food intake or hunger (pubmed.ncbi.nlm.nih.gov). The study links this to altered dopamine signaling in the nucleus accumbens—brain circuitry that drives motivation (pmc.ncbi.nlm.nih.gov). Motivation, not physical capacity, appears to be the change driver.
A systematic review found most studies (5 of 7) noted lower free‑living activity in adults using GLP‑1 RAs, though structured exercise often stayed stable (nature.com). One study documented a significant drop of about 1,144 steps per day with liraglutide (nature.com). Some patients using high‑dose tirzepatide reported emotional “flatness” or lost interest in exercise—anhedonia‑like symptoms—despite weight loss, which improved with dose adjustment (sciencedirect.com).
Why might reduced activity motivation occur on GLP‑1s?
Animal studies link semaglutide to lower voluntary exercise and altered dopamine activity, suggesting motivation shifts rather than physical weakness.
Do people on GLP‑1s physically lose strength or stamina?
Real‑world data points to less spontaneous movement, not loss of physical ability. Patients may feel less inclined to move even though their strength may remain.
Can structured exercise stay the same on GLP‑1s?
Yes. Evidence shows spontaneous activity may drop while planned or supervised workouts remain stable.
Have people reported emotional or motivational side effects on GLP‑1s?
Yes. A case series reported anhedonia‑like symptoms, such as lack of interest in exercise, on high‑dose tirzepatide, which improved after dose changes.
What can someone do if their movement motivation drops on GLP‑1s?
Awareness helps. Discuss it with a healthcare provider and consider structured activity and behavioral support to stay active.
This article is for general information and is not medical advice. GLP-1 medications are prescription drugs that require clinical supervision — talk to a licensed healthcare provider before starting, stopping, or changing any treatment.